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http://www.biomedcentral.com/1471-230X/14/162RESEARCH ARTICLE Open AccessCompletion rate of small bowel capsule endoscopy
is higher after erythromycin compared to
domperidone
Jessie Westerhof, Rinse K Weersma, Reinier A Hoedemaker and Jan J Koornstra*Abstract
Background: In up to 30 percent of small bowel capsule endoscopy procedures, the capsule does not reach the
cecum within recording time. A prolonged gastric transit time has been recognized as a risk factor for incomplete
capsule endoscopy. The aim of this study was to analyze if a single dose of orally administered erythromycin prior
to capsule endoscopy results in a higher completion rate compared to orally administered domperidone.
Methods: Single centre, non-concurrent prospective cohort study, 649 capsule endoscopy procedures were included.
Cecal completion rates, gastric and small bowel transit times and diagnostic yield were analyzed.
Results: 239 patients received erythromycin, 410 patients received domperidone. The cecal completion rate was 86%
after erythromycin versus 80% after domperidone (p = 0.03). After excluding known risk factors for incomplete capsule
endoscopy such as hospitalization and previous abdominal surgery, erythromycin still resulted in an increased completion
rate (p = 0.04). Median gastric transit time was lower after erythromycin compared to domperidone (13 min versus
22 min, p < 0.001). Median small bowel transit times were similar in both groups (236 min versus 248 min, p = 0.21).
Conclusions: In this study, the largest to date on this subject, the cecal completion rate was higher with erythromycin
than with domperidone, but there was no difference in the diagnostic yield.Background
Small bowel capsule endoscopy (CE) has become an estab-
lished technique to explore the small bowel. An important
limitation of small bowel capsule endoscopy is that in up to
30% of the procedures, visualization of the small bowel is
incomplete because the capsule does not reach the cecum
within recording time. This may lead to inconclusive proce-
dures and the need for repeated investigations [1].
We have previously shown that one of the risk factors
for incomplete CE is a long gastric transit time (GTT) [1].
Hence, there is a rationale to use prokinetic agents prior to
the procedure to decrease GTT and thereby potentially in-
crease the rate of complete small bowel examinations. A
prokinetic agent that has been studied often in this setting
is erythromycin [2-6]. Next to its bactericidal activity,
erythromycin induces high amplitude gastric propulsive
contractions by activating the gastric phase III interdigestive* Correspondence: j.j.koornstra@umcg.nl
Department of Gastroenterology and Hepatology, University Medical Centre
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article, unless otherwise stated.migrating motor complex, thereby accelerating gastric
emptying [7-12].
A recent meta-analysis on prokinetic agents and the
completion rate in small-bowel capsule endoscopy showed
that the use of prokinetics overall improved the comple-
tion rate, without influencing the diagnostic yield [13].
Previous studies on the effects of erythromycin in capsule
endoscopy suggested no beneficial effect of erythromycin
on capsule endoscopy completion rates [2-6], but it must
be realized that these studies are probably underpowered,
as no study included more than 50 patients per treatment
arm. The primary aim of the our study was to analyze
whether a single dose of orally administered erythromycin
prior to capsule endoscopy results in higher completion
rates compared to domperidone in a prospective cohort
study in 649 patients. Secondary endpoints were differ-
ences in GGT, small bowel transit time (SBTT) and the
diagnostic yield of CE.tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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Patients
We performed a prospective non-concurrent cohort study.
Our study has adhered to the STROBE guidelines for ob-
servational studies. Data from all consecutive CE proce-
dures performed at our Department, which is a tertiary
referral center, between March 2005 and May 2010, were
collected. Between March 2005 and July 2008, patients
received 10 mg of oral domperidone directly before the
procedure as part of the preparation. From July 2008 to
May 2010, we changed our strategy to giving 250 mg of
erythromycin orally 1 hour before the procedure. The
cohorts were therefore sequential and data were analyzed
retrospectively in a so-called non-concurrent cohort study
design.
Collected data included patient demographics, hospi-
talization and previous abdominal surgery, indication for
the procedure and CE findings. The most relevant find-
ings obtained from CE were documented and categorized
according to standard terminology [14] as angiectasia(s);
ulcer(s); bleeding of unknown origin; erosion (s); polyp(s)/
tumor(s); incidental abnormality of esophagus, stomach,
or colon; no abnormality; or unable to make a diagnosis.
Main outcome measurements were completion rates,
GTT, SBTT, and the diagnostic yield. The GTT was de-
fined as the time, in minutes, from the first image of the
stomach until the first image of the duodenum. The SBTT
was defined as the passage time, in minutes, from the first
image of the duodenum until the first image of the cecum.
If the capsule did not reach the cecum within recording
time, the SBTT was calculated by subtracting the GTT
from the total recording time. CE was considered complete
when the cecum was reached within recording time. The
diagnostic yield was defined as the percentage of positive
findings of CE.CE procedure
All patients were given standardized instructions before
the procedure, and informed consent was obtained. The
patients were asked to stop iron supplements seven days
before CE and to use a low-fiber diet three days before
the procedure. The patients started a fasting period at
midnight before the procedure. Bowel preparation consisted
of the ingestion of four liters of a polyethylene glycol solu-
tion (Colofort®), 3 liters the evening before the procedure
and 1 liter in the morning. Bowel prepration was given as it
has been shown that it increases the diagnostic yield of the
procedure [15]. The capsule (PillcamSB; Given Imaging Ltd,
Yoqneam, Israel) was swallowed in the morning. The
patients were allowed to drink fluids after three hours
and to consume a light meal after five hours. Before
capsule ingestion, 10 mL of antifoam was given. It must be
noted that during the study period no other changes weremade with respect to the capsule endoscopy procedure
except the choice of prokinetic agent.
From March 2005 to July 2008, 10 mg domperidone was
given orally directly prior to the procedure. Data from 410
consecutive patients were collected. Starting July 2008,
250 mg of erythromycin instead of domperidone was ad-
ministered orally one hour before capsule ingestion. Using
this regimen, data from 239 consecutive patients were col-
lected. Patients in whom the capsule was released by an
endoscope in the duodenum were excluded. Technical fail-
ures were also excluded. CE recordings were reviewed by
two gastroenterologists, experienced with capsule endos-
copy (RKW and JJK). Controversial findings were discussed,
and consensus was reached upon the final diagnosis. Dur-
ing the study period no modifications were made in the
capsule technology with 8 hours of recording time during
the entire period. The study protocol was approved by
the Local Institutional Review Board: the Medical Ethics
Committee of the University Hospital Groningen.
Statistical analysis
Statistical analysis was performed by using the Student t
test for normally distributed continuous variables and the
Chi-square test for non-continuous variables. The Mann–
Whitney test was used for data that were not normally dis-
tributed. P-values below 0.05 were considered significant.
SPSS 16.0 for Windows software (SPSS Inc., Chicago, IL,
USA) was used for all statistical analyses.
Results
Patients and findings
In total, 649 patients were included. 410 patients received
domperidone and 239 patients received erythromycin.
Baseline patient characteristics, indications for CE and
findings of the procedures are summarized in Table 1.
Overall, the two groups were fairly comparable. Median
age was slightly lower in the domperidone group: 55 years
(range 9–93) and 60 years (range 18–89) in the erythro-
mycin group (p = 0.03) and in the domperidone group,
the indications for the procedure was more often occult
gastrointestinal bleeding.
Number of complete CE procedures
The number of complete CE procedures in the erythro-
mycin group was 86% (95% CI 81-90%) versus 80% in the
domperidone group (95% CI 76-83%; p = 0.03). Previous
small bowel surgery and hospitalization are known risk
factors for incomplete CE procedures [1]. To exclude the
influence of these known risk factors we also performed
the analysis after exclusion of patients with these know
risk factors in both groups. When these patients were ex-
cluded, leaving 488 patients for analysis, the difference be-
tween the domperidone and the erythromycin group was
Table 1 Baseline patient characteristics, indications and
findings
Domperidone Erythromycin p
Number of patients 410 239
Male (n,%) 192 (47) 108 (45) 0.69




253 (62) 183 (77)
- overt gastro-intestinal
bleeding
53 (13) 20 (8)
- suspected Crohn’s disease 104 (25) 36 (15)
Findings (n,%)
- angiodysplasia(s) 58 (14) 57 (24)
- erosion(s) 62 (15) 14 (6)
- ulcera 25 (6) 11 (5)
- polyp(s)/tumor(s) 37 (9) 19 (8)
- active bleeding 22 (5) 5 (2)
- no abnormalities 206 (50) 133 (56)
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group, 85% in the domperidone group, p = 0.035).
Gastric and small bowel transit time
The GTT was significantly shorter (median 13 minutes, 25
and 75 percentiles; 12 and 54 minutes) in the erythromycin
group than in the domperidone group (median 22 minutes,
25 and 75 percentiles; 7 and 27 minutes), p < 0.01 (Figure 1).
There was no difference in SBTT between both groups:
median 248 minutes in the domperidone group (25 and 75
percentiles: 197 and 336 minutes) and 237 minutes (25 and
75 percentiles; 156 and 347 minutes) in the erythromycin
group, p = 0.21.Figure 1 Box plot depiction of gastric transit times in the
erythromycin group compared to the domperidone group
(median 13 versus 22 minutes, p < 0.01).Diagnostic yield
There was no significant difference in the diagnostic
yield between both groups: 50% in the domperidone
group versus 44% in the erythromycin group, p = 0.18.Discussion
In this prospective non-concurrent cohort study, the
rate of complete capsule endoscopy procedures was
higher using the prokinetic agent erythromycin compared
to domperidone. We found that erythromycin shortened
the gastric transit time without influencing the small bowel
transit time or diagnostic yield. These findings remained
significant after excluding hospitalized patients and pa-
tients with previous small bowel surgery, known risk fac-
tors for incomplete CE procedures.
Previous studies found conflicting data on the use of
erythromycin as a prokinetic agent in capsule endoscopy.
Most studies found an acceleration of the GTT, although
not significant in all studies, without actual improving
completion rates [2-6,13]. The latter is undoubtedly due
to small patients groups in previous studies. Our power
analysis revealed that at least 199 patients needed to be
studied in both arms, whereas previous studies included
no more than 50 patients in each treatment arm.
In previous studies erythromycin was effective in redu-
cing GTT in humans and animals with gastric paresis
[11,12]. In the literature on erythromycin as a prokinetic
agent in CE, some studies found a significantly reduced
GTT [3,4] but none reported an effect on SBTT, total
transit time or improved completion rates [2-6,13]. Some
found a non-significant reduction in GTT [2,5,6]. Most
studies compared erythromycin to placebo or no agent
with equal bowel preparations in both groups [2-5]. In
one study bowel preparation was different in the study
groups making the interpretation of the effect of erythro-
mycin difficult [6]. Finally, one study used real time view-
ing with on demand use of erythromycin to facilitate the
passage of the capsule into the small bowel. In this study
the completion rate of CE was higher in the group that
used erythromycin on demand [16].
Since we previously showed that a prolonged gastric
transit time was a risk factor for incomplete capsule
endoscopy procedures [1], and there was evidence that
erythromycin may decrease GGT, we started adminis-
tering erythromycin prior to CE. We used a dosage of
250 mg erythromycin given orally 1 hour before the
procedure, because it was safely used in previous stud-
ies and reduced GTT in those studies [2,3,5]. However,
a study on pharmacokinetics of erythromycin as a pro-
kinetic agent showed that erythromycin suspension may
be superior to administration of a tablet [17]. It can be
speculated that the results might improve with the use of
erythromycin suspension.
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largest study population on this subject, supported by
fulfillment of power calculation criteria. A limitation of
our study design is that it was non-randomized, and also
not placebo-controlled. Instead, we compared erythromycin
to domperidone before and after a certain time point. It
should be noted that except for the change in prokinetic
agent no other modifications were made with respect to
capsule preparation or protocol during the entire study
period. We initially used domperidone as a prokinetic agent
prior to capsule endoscopy, because several studies at that
time showed improved gastric emptying in patients with
diabetic gastroparesis [18]. A recent study on domperidone
showed that it also improves the completion rate of capsule
endoscopy without influencing the diagnostic yield [19].
Furthermore, it lacks the extrapyramidal adverse effects of
the more widely used metoclopramide. From July 2008 on-
ward, erythromycin was given instead of domperidone. Our
results may have been different when the drug had been
compared to placebo. It must be noted that the mean
gastric transit time in our study was 13 minutes for
erythromycin and 22 minutes for domperidone, com-
pared to 34 minutes in a recent large study on capsule
endoscopy in 540 outpatient CE procedures receiving
no prokinetic agent [20]. In inpatient procedures, it was
even longer, associated with a completion rate of only 70%
[20]. We did not compare the number of hospitalized pa-
tients between both groups. However after excluding pa-
tients with an in-hospital CE procedure, which is a known
risk factor for incomplete CE procedures [1], the differ-
ence between the domperidone and the erythromycin
group became even more significant.
A drawback of using erythromycin as a prokinetic agent
may be the development of bacterial resistance. However,
since erythromycin is given as a single dose, it can be as-
sumed to be associated with a smaller chance of bacterial
resistance development compared tot a long course of anti-
biotics. Similarly, the use of a single dose of erythromycin
in the setting of massive upper gastrointestinal bleeding
prior to endoscopy is widely accepted [21]. Nevertheless, if
an equally effective, non antibiotic, prokinetic agent became
available, it would be preferable to use over erythromycin.
Comparing the baseline characteristics in the two groups,
we noted that there were slightly significantly more patients
with Crohn’s disease in the domperidone group than in the
erythromycin group and that the mean age in this group
was slightly younger. One could imagine that in patients
with strictures or inflammation in Crohn’s disease, the cap-
sule may take more time to pass the small bowel. However,
we do not expect that this influenced our results as we
showed that the beneficial effect of erythromycin could be
attributed to acceleration of the GGT, while SBTT was
not significant different between both groups. Looking
at the other baseline characteristics both groups werequite similar. Overall this is the largest study to date
showing that erythromycin effective increases the rate
of complete capsule endoscopy procedures. Potential
applications in clinical practice may be to administer
erythromycin in patients with expected prolonged GGT
or patients with previously incomplete CE investigations.
Alternatively, erythromycin may be considered when a
real time viewer suggests gastric retention. In our practice,
erythromycin is administered prior to every CE. It is likely
that technical improvements such as longer battery times
will further improve capsule endoscopy completion rates
in the future.
Conclusions
In the largest study to date, orally administered erythro-
mycin prior to CE increased the number of complete cap-
sule endoscopy procedures compared tot domperidone by
accelerating the gastric transit time. However, the diagnos-
tic yield was similar in both groups.
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